Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865885 | 0.93 | MLNR (0.38) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL4873477 | 0.90 | MLNR (0.47) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL4862489 | 0.89 | MLNR (0.47) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL4866060 | 0.86 | ABCB1 (0.49) | LMNAALDH1A1HTT | |
| SCHEMBL6619976 | 0.85 | MLNR (0.43) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL1600975 | 0.84 | MLNR (0.45) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL4873029 | 0.83 | PDE4A (0.47) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7251478 | 0.83 | PDE4A (0.47) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4159704 | 0.83 | MLNR (0.44) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL4864734 | 0.83 | PDE4A (0.39) | PDE4DPDE4APDE4BPDE4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | MLNR 4045/4885ABCB11 1899/4885LMNA 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.